Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis

Blacker, David J; Gray, Faye; Byron, Keith

doi:10.5694/j.1326-5377.2005.tb06742.x

Topics

To the Editor: The recent position statement from the Warfarin Reversal Consensus Group provides a comprehensive, coherent and practical approach to warfarin reversal management. 1

Gribbles Pathology, 1868 Princess Highway, Clayton, Melbourne, VIC 3168.

Correspondence:

1. Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 492-497. <eMJA full text>
2. Freeman BD, Zehnbauer BA, McGrath S, et al. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 2000; 128: 281-285.
3. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-719.
4. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-349.
5. You JH, Chan FW, Wong RS, et al. The potential clinical and economic outcomes of pharmacogenetics-orientated management of warfarin therapy — a decision analysis. Thromb Haemost 2004; 92: 590-597.

Online responses are no longer available. Please refer to our instructions for authors page for more information.